3D graphic showimg a CAR T cell killing a cancer cell
3D graphic showimg a CAR T cell killing a cancer cell
Logo

Clinical-grade gamma delta (γδ) T cell manufacturing for immunotherapy

The CliniMACS Prodigy® Platform enables the automated manufacturing of gamma delta (γδ) T cells. All processing steps – from efficient γδ T cell enrichment, activation, and expansion to optional engineering by viral transduction and final product harvest – are carried out in a closed system. The result is a robust and simplified workflow that facilitates the development of novel γδ T cell therapies.

Simplified manufacturing of γδ T cells on the CliniMACS Prodigy

Gamma delta T cells, also known as γδ T cells or TCRγ/δ+ T cells, are frontline immune cells that defend against infections and have unique roles in immune surveillance and tissue homeostasis.1 Unlike αβ T cells, their T cell receptor (TCR) configuration consists of γ and δ chains, which grants them the ability to recognize a broader array of antigens in an HLA-independent manner.1,2 Two major subsets of γδ T cells are recognized according to their Vδ chain usage. The main γδ T cell subset in peripheral blood uses Vδ2, while T cells using Vδ1 are predominant in epithelial tissues.1–3

Studies have demonstrated that γδ T cells can eliminate tumor cells from both solid and hematologic malignancies.4–7 Additionally, their infiltration into tumors seems to be the most positive prognostic marker in many cancers.8 With immunomodulatory functions and a low risk of causing graft-versus-host disease (GVHD), γδ T cells are important effector cells for adoptive cell immunotherapy. 2,3,9,10 Genetic engineering, such as generating CAR γδ T cells, can further enhance their cytotoxicity and direct them toward specific targets.1–3,9,10

Manufacturing clinical-grade γδ T cells is challenging and difficult to scale up. Miltenyi Biotec is catalyzing progress in this field with a straightforward and automated manufacturing process on the CliniMACS Prodigy Platform.

Two proven processes are combined into an efficient γδ T cell manufacturing workflow

Our workflow concatenates our processes for TCRα/β+ (αβ) T cell depletion and T cell manufacturing to enable the standardized manufacturing of γδ T cells. The workflow processing steps are automated and take place in sterile, single-use consumables, ensuring efficient and reliable outcomes.

FeatureSpecification
Starting materialγδ T cells freshly enriched from leukapheresis products, either on the CliniMACS Plus or the CliniMACS Prodigy
Culture capacity (volume)600 mL
Final T cell count (total)approx. 7×109 total γδ T cells

Process 1: Depletion of TCRα/β+ and CD19+ cells

The first process enriches γδ T cells from leukapheresis products by depleting TCRα/β+ and CD19+ cells using either the CliniMACS® Plus or the CliniMACS Prodigy Instrument.

Process 2: Activation, transduction, and expansion of γδ T cells

In the second process, the γδ T cells resulting from process 1 on the CliniMACS Plus or the CliniMACS Prodigy are activated, transduced (optional), and cultivated on the CliniMACS Prodigy, leading to the preferential expansion of Vδ2 T cells.

Webinar

Enabling clinical-grade automated manufacturing of γδ T cells

In this webinar, discover innovative approaches to γδ T cell manufacturing, and key considerations for setting up manufacturing workflows for this unique cell population. Learn how the CliniMACS Prodigy® Platform can automate the GMP-compliant expansion of Vδ2 T cells, and how these cells can be efficiently transduced using a baboon envelope (BaEV)-pseudotyped lentiviral vector. Find out more about the flow cytometry tools that support analytical testing and contribute to streamlining process validation for pioneering γδ T cell therapies.

From starting material to γδ T cell product in four steps

As a complete workflow, γδ T cells are manufactured in four steps, which are detailed below. The first step, enrichment of γδ T cells, can be carried out on either the CliniMACS Plus or the CliniMACS Prodigy via depletion of TCRα/β+ and CD19+ cells in process 1. All remaining steps – from activation through expansion – are carried out on the ClinMACS Prodigy in process 2.

1. γδ T cell enrichment (process 1)

Infographic showing the principle of magnetic cell separation

Starting from fresh leukapheresis products, γδ T cells are efficiently enriched using the CliniMACS TCRα/β and CliniMACS CD19 Product Lines combined with either the CliniMACS Plus or the CliniMACS Prodigy Instrument. The process depletes TCRαβ+ T cells and CD19+ B cells to obtain a cell fraction enriched with γδ T cells. Subsequent processing of the enriched γδ T cells is carried out on the CliniMACS Prodigy.

2. γδ T cell activation (process 2)

Activation of gamma delta T cells on the CliniMACS Prodigy Platform

Vδ2 T cells are the major subset of γδ T cells found in peripheral blood. They can be activated by natural or synthetic phosphoantigens as well as by aminobisphosphonate compounds11. Aminobisphosphonates, such as zoledronic acid or pamidronic acid, alter the mevalonate pathway of monocytes and other antigen-presenting cells, thereby inducing the expression of cell surface molecules that are structurally similar to ligands recognized by the TCR of Vδ2 T cells11,12. Upon treatment with aminobisphosphonates, monocytes remaining after depletion of TCRαβ+ T cells activate the Vδ2 T cells present in the enriched fraction. Activation can be promoted by adding MACS GMP Cytokines.

3. γδ T cell transduction (process 2)

Viral transduction of gamma delta T cells on the CliniMACS Prodigy Platform

Optionally, the activated γδ T cells can be genetically engineered with viral vectors. The transduction process enables stable genomic insertion and can be programmed to accommodate your specific protocol.

Furthermore, using Vectofusin®-1 boosts γδ T cell transduction efficiency and is compatible with both static and spinoculation protocols.

Two employees wearing clean room attire sharing data.
CDMO services from Miltenyi Bioindustry

A suitable lentiviral vector for your hard-to-transduce cells

The baboon envelope pseudotyped (BaEV) lentiviral vector (LVV) platform enhances the engineering possibilities for hard-to-transduce cells such as γδT cells, NK cells, or hematopoietic stem cells. Leverage the same proven manufacturing platform from Miltenyi Bioindustry but with a new envelope.

Expand your options

4. γδ T cell expansion (process 2)

Expansion of gamma delta T cells on the CliniMACS Prodigy Platform

Whether transduced or untransduced, the activated Vδ2 T cells are expanded in the cell cultivation chamber of the CliniMACS Prodigy. As part of the closed CliniMACS Prodigy Tubing Set, the chamber maintains optimal cell growth conditions with programmable culture duration, medium supply, and medium exchange.

Efficient expansion of Vδ2 T cells relies on the strong synergy of the TexMACS GMP Medium and MACS GMP Cytokines IL-2 and IL-15.

Icon showing a hand supporting a person and gear icon
Customized Application Services

Customized solutions for γδ T cell manufacturing

Are you working with a starting material other than leukapheresis products? Are you interested in targeting a different γδ T cell subset? Our Customized Application Services work with you to customize solutions to your specific needs.

Quality control testing by clinical flow cytometry

MACSQuant Analyzer 16 flow cytometer with touchscreen software interface and sample tubes on benchtop

In order to enable safe and consistent cell manufacturing, the implementation of robust in-process controls and release testing (IPC/RT) is crucial.

Samples collected within the manufacturing process, e.g., on the CliniMACS Prodigy, are reliably analyzed on our standardized flow cytometry platform. Our comprehensive workflow solution comprises harmonized MACSQuant® Flow Cytometers, automated data acquisition and analysis (Express Modes) in an audit-ready software, and a broad portfolio of REAfinity® Recombinant Antibodies with superior specificity and reproducibility. Miltenyi Biotec provides comprehensive solutions with pre-tested, ready-to use multicolor panels and options for cytokine multiplexing.

Find more information on analytical solutions for cell and gene therapy.

Get personalized support for your manufacturing of clinical-grade γδ T cells

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. For complete regulatory notes, please click here.

You have previously chosen International as your location.
What do you want to do?